Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Express Scripts
Medtronic
Dow
Cerilliant
Citi
Harvard Business School
Chubb
UBS

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,151,102

« Back to Dashboard

Summary for Patent: 7,151,102
Title:Phthalazinone derivatives
Abstract: A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula: ##STR00001## or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein: A and B together represent an optionally substituted, fused aromatic ring; R.sub.C is represented by --L--R.sub.L, where L is of formula: --(CH.sub.2).sub.n1-Q.sub.n2-(CH.sub.2).sub.n3-- wherein n.sub.1, n.sub.2 and n.sub.3 are each selected from 0, 1, 2 and 3, the sum of n.sub.1, n.sub.2 and n.sub.3 is 1, 2 or 3 and Q is selected from O, S, NH, C(.dbd.O) or --CR.sub.1R.sub.2--, where R.sub.1 and R.sub.2 are independently selected from hydrogen, halogen or optionally substituted C.sub.1-7 alkyl, or may together with the carbon atom to which they are attached form a C.sub.3-7 cyclic alkyl group, which may be saturated (a C.sub.3-7 cycloalkyl group) or unsaturated (a C.sub.3-7 cycloalkenyl group), or one of R.sub.1 and R.sub.2 may be attached to an atom in R.sub.L to form an unsaturated C.sub.3-7 cycloalkenyl group which comprises the carbon atoms to which R.sub.1 and R.sub.2 are attached in Q, --(CH.sub.2).sub.n3-- (if present) and part of R.sub.L; and R.sub.L is optionally substituted C.sub.5-20 aryl; and R.sub.N is selected from hydrogen, optionally substituted C.sub.1-7 alkyl, C.sub.3-20 heterocyclyl, and C.sub.5-20 aryl, hydroxy, ether, nitro, amino, amido, thiol, thioether, sulfoxide and sulfone.
Inventor(s): Martin; Niall Morrison Barr (Cambridge, GB), Smith; Graeme Cameron Murray (Cambridge, GB), White; Charles Richard (Carlisle, GB), Newton; Roger Frank (Cornwall, GB), Douglas; Diane Gillian (Cornwall, GB), Eversley; Penny Jane (Cornwall, GB), Vile; Julia (Cornwall, GB)
Assignee: Kudos Pharmaceuticals Limited (Cambridge, GB) Maybridge PLC (Cornwall, GB)
Application Number:10/021,506
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,151,102

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,151,102

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0026505.8Oct 30, 2000

Non-Orange Book US Patents Family Members for Patent 7,151,102

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,750,006 Phthalazinone derivatives ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,151,102

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 496034 ➤ Try a Free Trial
Australia 2001295789 ➤ Try a Free Trial
Australia 9578901 ➤ Try a Free Trial
Brazil 0115062 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Federal Trade Commission
Cerilliant
Chubb
Covington
Harvard Business School
US Army
Healthtrust
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.